Intercure annual ebitda
2019
2020
2021
2022
2023
2024
2025
Intercure EBITDA Growth & History (INCR)
Intercure's calculated EBITDA was −₪7.3M for fiscal 2025.
View full Intercure company overviewIntercure annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −₪7.3M | ₪44.5M | — |
| 2024 | 2024-12-31 | −₪51.8M | −₪23.4M | — |
| 2023 | 2023-12-31 | −₪28.4M | −₪90.7M | — |
| 2022 | 2022-12-31 | ₪62.3M | ₪26.7M | +75.18% |
| 2021 | 2021-12-31 | ₪35.6M | ₪70.7M | — |
| 2020 | 2020-12-31 | −₪35.1M | −₪32.6M | — |
| 2019 | 2019-12-31 | −₪2.6M | — | — |
Intercure ebitda trends
Over the last five fiscal years, Intercure's ebitda increased from −₪35.1M to −₪7.3M, a change of ₪27.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Intercure source filings ↗Community posts
InterCure resolves Nasdaq minimum-bid-price deficiency
InterCure ($INCR) received written confirmation that it has regained compliance with Nasdaq’s minimum-bid-price requirement. Its shares had closed at or above $1 for ten consecutive business days, allowing Nasdaq to close the specific defic ...
